Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain

Frontiers in Oncology

Radosław Chaber¹  Katarzyna Szewczyk²  Mirosław Bik-Multanowski²  Monika Pogorzała³  Mariusz Wysocki³  Walentyna Balwierz⁴  Aleksandra Wieczorek⁴  Wojciech Młynarski⁶  Szymon Janczar⁶  Zuzanna Gamrot⁷  Mariola Woszczyk⁷ 

[1] Clinic of Pediatric Oncology and Hematology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland;Department of Medical Genetics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland;Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland;Department of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, Krakow, Poland;Department of Pediatrics Oncology and Hematology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland;Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland;Unit of Pediatric Oncology and Hematology, City Hospital, Chorzow, Poland;

关键词: 2p gain;    MYCN gain;    MYCN amplification;    neuroblastoma;    structural chromosomal aberrations;   

DOI  :  10.3389/fonc.2019.01018

来源: DOAJ

【 摘 要 】

Background: Amplification of the MYCN oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of MYCN is still insufficient. Therefore, we aimed to investigate the disease course in patients with different copy number status of MYCN.Materials and Methods: We examined 105 children diagnosed with neuroblastoma from 2010 to 2018 in five pediatric oncology centers in Poland. We determined the MYCN status at diagnosis by the interphase FISH examination and assessed the clinical outcome in patients.Results: A total of 35% of tumors presented with chromosome 2 numerical changes, 20% had MYCN amplification and 16% revealed 2p gain. Unexpectedly, we observed very low overall survival and event free survival (EFS) rates in neuroblastomas with 2p gain, which were comparable with patients with MYCN amplification.Conclusions: The 2p gain alteration should be reported as a strong unfavorable prognostic marker in neuroblastoma patients.

【 授权许可】

Unknown